Corcept Stock Tanks 50% After FDA Rejection, Class Action Lawsuit Filed

Kirby McInerney LLP has filed a securities class action lawsuit against Corcept Therapeutics Incorporated ($COPT) on behalf of investors who purchased shares during a critical period when the company allegedly misrepresented the strength of clinical trial data supporting its flagship drug candidate. The lawsuit centers on claims that Corcept made misleading statements about its relacorilant application to the FDA, presenting the clinical evidence as "powerful support" while expressing confidence in approval—assertions that proved catastrophically false when regulators issued a Complete Response Letter denying the drug's authorization.

The dramatic stock collapse that followed has left investors nursing significant losses and sparked legal action that underscores the high-stakes nature of biotech investing and the critical importance of accurate clinical trial communication to the investment community.

The Clinical Trial Controversy and FDA Rejection

Corcept Therapeutics faces serious allegations regarding how it characterized its relacorilant development program to investors and the market. According to the class action filing, the company represented that clinical trial data provided "powerful support" for its FDA application and expressed confidence in regulatory approval. These statements allegedly masked what the FDA itself had been communicating privately to Corcept: repeated concerns about the adequacy of the clinical evidence supporting the drug application.

The disconnect between Corcept's public optimism and the FDA's private reservations became starkly apparent on December 31, 2025, when regulators issued a Complete Response Letter denying approval for relacorilant. The decision delivered a devastating blow to investor confidence and company prospects:

• Stock price collapse: $COPT plummeted 50.4%, falling from $70.20 to $34.80 following the FDA announcement
• Investment period under scrutiny: The lawsuit covers investors who purchased shares between October 31, 2024 and December 30, 2025—a 14-month window during which Corcept allegedly made misleading statements about the drug's regulatory pathway
• Lead plaintiff deadline: Investors have until April 21, 2026 to become lead plaintiffs in the litigation

The timing of the disclosure—on the final day of 2025—raised additional questions about whether Corcept had advanced notice of the FDA's decision and, if so, when shareholders should have been informed.

Market Context: Biotech Volatility and Regulatory Risk

The Corcept situation exemplifies the extreme volatility inherent in biotech equities, where regulatory decisions from the FDA can instantly erase billions in market value. The pharmaceutical and biotechnology sector depends fundamentally on clinical trial data integrity and accurate representation of regulatory interactions—elements that form the foundation of investor decision-making.

Relacorilant was a significant asset for Corcept Therapeutics, which focused on cortisol-related disorders. The drug's fate was critical to the company's growth trajectory and valuation. For a mid-cap biotech company, a single FDA rejection of a lead candidate can be existential, as it often signals questions about the company's scientific approach, data quality, or ability to interpret regulatory feedback.

The regulatory environment around biotech disclosures has intensified in recent years:

• SEC scrutiny: Securities regulators have heightened focus on forward-looking statements by biotech companies regarding clinical trials and FDA interactions
• Disclosure standards: Companies are expected to provide balanced representations of clinical data and regulatory feedback, avoiding selective optimism
• Material information: Any indication from regulators about approval challenges must be disclosed to investors in timely fashion
• Comparative landscape: Similar class actions have targeted other biotech firms for alleged misstatements regarding clinical trial strength or FDA communications

The securities litigation against Corcept arrives amid broader investor concerns about biotech valuations and the reliability of clinical development narratives.

Investor Implications and Litigation Landscape

The class action lawsuit filed by Kirby McInerney LLP carries significant implications for shareholders who invested in Corcept during the period when the company allegedly misrepresented its regulatory position. Several investor classes face distinct challenges:

Those holding shares through the collapse have experienced realized or unrealized losses of approximately 50% in a matter of hours. The lawsuit alleges they were misled about the fundamental strength of Corcept's most important drug development program.

The legal process typically follows a predictable path in securities class actions:

1. Lead plaintiff selection (deadline April 21, 2026)
2. Case certification as a class action
3. Discovery phase examining internal communications and FDA interactions
4. Potential settlement negotiations or trial

The discovery process in this litigation could prove illuminating regarding what Corcept knew about FDA concerns and when senior management became aware of regulatory skepticism. Internal emails, regulatory correspondence, and board materials may shed light on the gap between public statements and private FDA communications.

Settlement potential: Securities class actions in the biotech sector frequently resolve through settlements rather than trials. The amount recovered typically depends on the company's insurance coverage, defendants' resources, and the strength of evidence regarding scienter (knowledge of falsity).

Broader implications: The Corcept case will likely intensify scrutiny of how biotech companies characterize FDA interactions and clinical trial data in investor communications, press releases, and SEC filings. Regulatory agencies may also review Corcept's specific disclosures as a case study in misleading statements.

Looking Ahead: Questions About Company Viability

Beyond the litigation, Corcept Therapeutics faces fundamental questions about its corporate viability and strategic direction. The rejection of relacorilant eliminates what appeared to be the company's primary near-term growth catalyst. The company must now:

• Assess whether additional clinical data or modified trials could support a resubmission
• Evaluate its remaining pipeline candidates and timeline to regulatory decision points
• Manage the reputational damage from the FDA rejection and alleged investor misstatements
• Potentially explore strategic alternatives, partnerships, or restructuring

The stock price recovery will depend heavily on Corcept's ability to articulate a credible path forward and demonstrate transparent, accurate communication with the investment community going forward. The 50% decline has already inflicted substantial investor losses, and the legal liability adds another layer of risk.

For investors in biotech equities broadly, the Corcept episode serves as a sobering reminder of the dangers inherent in relying solely on management's optimistic characterizations of regulatory interactions. Prudent investors should carefully parse SEC filings for balanced disclosure of FDA feedback and clinical trial limitations, recognizing that regulatory risk remains one of the most significant factors in biotech valuations.